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Reduced bone mineral density in adults treated with high-dose
corticosteroids for childhood nephrotic syndrome.
Background. Children with minimal change nephrotic syn-
drome (MCNS) receive repeated courses of high dose oral pred-
nisolone. No previous study has investigated the impact of this
on final bone mineral density (BMD). Young adults previously
reported in a large follow-up study of children with MCNS were
invited to participate in a cross-sectional study. Areal BMD
(aBMD) of the spine (L1-4), left femoral neck, and total left
hip was measured using dual x-ray absorptiometry (DXA), and
volumetric BMD (vBMD) of the distal radius was measured by
pQCT. BMD results were compared with reference data pro-
vided by the manufacturers of the densitometers.
Methods. Thirty-four (24 male) of the original cohort of 62
participated in the study. The mean (SD) final height Z score of
the cohort was –0.45 (0.92) (P = 0.007) and mean BMI Z score
1.62 (1.53) (P < 0.0001).
Results. There was a highly significant reduction in distal ra-
dial trabecular vBMD; the mean Z score was –0.95 (0.99) and
T score –1.04 (1.01) (both P < 0.0001); however, there was no
reduction in distal radial total vBMD, the mean Z score being
0.00 (0.95) and T score −0.08 (0.99), (P = 0.99 and 0.66, respec-
tively). The aBMD of the lumbar spine and femoral neck also
showed a reduction in T scores [−0.45 (1.27), P = 0.045 and
−0.49 (0.86), P = 0.002, respectively], but not Z scores [−0.37
(1.28) and −0.15 (0.87), respectively, both P = NS]. Total hip
aBMD was not different from the control population.
Conclusion. Adult survivors of childhood MCNS have a sig-
nificant reduction in forearm trabecular vBMD, placing them
at increased fracture risk at this site.
Minimal change nephrotic syndrome (MCNS) is the
most common glomerular disease of childhood, with an
incidence of 2 to 7 per 100,000 child population. The dis-
ease presents with heavy selective proteinuria of acute
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onset, resulting in hypoalbuminemia and generalized
edema, and exhibits a rapid response to high-dose corti-
costeroid therapy. While some controversy exists regard-
ing the optimal duration of initial corticosteroid therapy
at disease presentation [1], historically, the large majority
of centers have used an 8-week regimen first described by
the International Study for Kidney Disease in Children
(ISKDC; prednis(ol)one 60 mg/m2 daily for 28 days fol-
lowed by 40 mg/m2 on alternate days for 28 days, the total
dose administered being 2.24 g/m2). Over 90% of chil-
dren will enter disease remission with resolution of pro-
teinuria and hypoalbuminemia following such a course
of therapy; however, around 80% will subsequently de-
velop disease relapses [2]. These are treated with further
courses of high-dose corticosteroid using the ISKDC re-
lapse regimen (predniso(lo)ne 60mg/m2 daily until 3 days
of zero or trace proteinuria followed by 40 mg/m2 on al-
ternate days for 28 days). At least 50% of children will
follow a frequently relapsing or steroid-dependent course
where alternative immunosuppressive therapies may be
necessary to prevent or reverse adverse effects of steroid
therapy. The disease has a tendency to undergo sponta-
neous remission during later childhood, such that 80%
of affected patients will enter adult life free from disease
relapses, though by this time point, the large majority of
affected children will have received a significant cumula-
tive corticosteroid dose.
Childhood, particularly adolescence, is a critical time
for the accrual of bone mass. Any chronic childhood ill-
ness or treatment thereof that interferes with the acquisi-
tion of normal bone mineral content may compromise the
achievement of an individual’s genetically programmed
peak bone mineral content. This may increase their risk
of developing osteoporotic fractures in adulthood. Osteo-
porosis and increased fracture risk have long been recog-
nized as complications of long-term treatment with oral
corticosteroids in adults [3]. Corticosteroids are known
to have multiple effects on bone, including direct effects
resulting in diminished bone formation and enhanced
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resorption, reduction of the lifespan of osteoblasts and
osteocytes, and promotion of osteoclast survival [4–6].
Of potential specific importance to children is the im-
pact of these agents on the synthesis and activity of
a variety of cytokines and growth factors, including
the insulin-like growth factors (IGF-I and IGF-II) and
their binding proteins (IGFBP-3, -4, and -5). Corticos-
teroids additionally induce reduced intestinal calcium ab-
sorption and increased urinary calcium excretion [7–9].
Corticosteroid-induced osteoporosis has a predilection
for the axial rather than the appendicular skeleton and
affects trabecular more than cortical bone.
Previous studies that have investigated bone mineral
density (BMD) using a variety of different methodologies
in children with minimal change disease have reported
conflicting results [10–16]. No previous study has investi-
gated the impact of corticosteroids administered during
childhood and adolescence on adult BMD.
The aims of this study were to examine the impact
of corticosteroid therapy throughout childhood on adult
BMD at axial and appendicular skeletal sites and growth
parameters in a cohort of patients with biopsy-proven
MCNS and comprehensive disease relapse histories.
METHODS
The study population was drawn from a cohort of 61
adults (46 male) with a history of childhood MCNS pre-
viously reported in a large follow-up study describing
relapse history, morbidity, and mortality [17]. All had pre-
sented to the Royal Manchester Children’s Hospital with
nephrotic syndrome between 1963 and 1976, had been
shown to have minimal change histology on renal biopsy,
and had responded to corticosteroid therapy. Compre-
hensive data on relapse history for up to 20 years post-
diagnosis were available from this previous study. The
presenting episode of nephrotic syndrome and all sub-
sequent relapses had been treated with standard courses
of prednisolone therapy using the ISKDC regimens de-
scribed above in all patients, thus allowing determination
of any relationship between cumulative corticosteroid ex-
posure and BMD.
Subjects were contacted through their general practi-
tioners and invited to participate in the study. The proto-
col was approved by the local research ethics committee
and subjects gave fully informed written consent for their
participation.
Height was measured to the nearest millimeter using
a wall-mounted stadiometer (Leicester Height Meter,
Child Growth Foundation, London, UK) and body
weight measured to the nearest 0.1 kg using digital scales
(Seca digita scales; Autoweigh Scales, Ltd., Elland, UK).
Body mass index (BMI) was calculated using the formula
kg/m2; individuals whose BMI was >25 kg/m2 were con-
sidered to be overweight and >30 kg/m2 obese. Height,
weight, and BMI were converted to standard deviation
scores (Z score) using standard reference curves for the
United Kingdom population [18, 19]. All subjects com-
pleted a questionnaire regarding their previous fracture
history.
Bone densitometry
A Hologic QDR-4500A (Hologic, Waltham, MA,
USA) dual x-ray absorptiometry (DXA) scanner was
used to measure areal bone mineral density (aBMD;
g/cm2) of the lumbar spine (LS; L1–L4), femoral neck
(FN), and total hip (TH). All analyses were performed
using software version V8.26a:3 (Vertec Scientific, Ltd.,
Reading, UK). The in vivo coefficients of variation (CV)
for LSaBMD, FNaBMD, and THaBMD were 1.09%,
3.29%, and 1.26%, respectively, in 10 adults scanned
twice. Peripheral quantitative computed tomography
(pQCT) measurements were made using a Stratec XCT-
2000 scanner (Stratec, Pforzheim, Germany). All mea-
surements were performed at the distal 4% site in the
nondominant arm in accordance with the manufacturer’s
recommendations, using software version 5.40b. The non-
dominant arm length was measured from the tip of the
elbow to the ulna styloid process, and a scout view was
taken to identify the end of the radius. A 1.2 mm thick
single tomographic slice was sampled using a scan speed
of 25 mm/sec and voxel size of 0.4 mm. The volumetric
bone mineral density (vBMD; mg/cm3) was determined
at the distal radius for the total cross-section (cortical
and trabecular) and for the trabecular (<400 mg/cm3)
compartment. The in vivo CV for total and trabecular
volumetric BMD at the distal radius was 0.78%.
The DXA and pQCT measured BMD parameters were
transformed into standard deviation scores (Z scores) us-
ing the age- and gender-specific reference data provided
by the manufacturers of densitometers used in this study.
BMD T-score, which is the number of standard deviations
from the value at peak BMD of young adults, was also
calculated for each subject.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism version 4.02 (GraphPad Software, San Diego, CA,
USA). Kolmogorov-Smirnov and D’Agostino and Pear-
son omnibus normality tests were used to determine
whether data were normally distributed. Where this was
the case, data were expressed as mean ± 1 standard
deviation and a one-sample Student t test was used
to determine whether mean Z scores for BMD and
anthropometric parameters were significantly different
from zero. Where data were not normally distributed,
these were expressed as median values with interquartile
ranges and the Mann-Whitney test was used to determine
whether the data differed from zero. The correlations
between number of disease relapses and BMD Z score
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Fig. 1. Scatter-plot of Z score of height of the study population. The
horizontal bar represents the mean value, which was significantly lower
than zero (one sample t test).
and other anthropometric parameters were assessed us-
ing the Pearson and Spearman correlation coefficients.
Significance was based on two-tailed tests; P < 0.05 was
considered to be significant.
RESULTS
A total of 34 (24 male) of the 61 subjects described pre-
viously [17] were traceable and agreed to participate in
the study. They had presented with nephrotic syndrome
at a median (interquartile range) age of 4.93 (2.51–7.89)
years and during childhood had suffered a median (in-
terquartile range) of 8.00 (3.00–15.00) disease relapses,
each of which was treated with prednisolone using the
standard ISKDC relapse regimen described above. Their
median (interquartile range) age at investigation was
35.50 (33.45–40.85) years and all were of white UK ethnic
origin. Thirty-three were entirely well and had suffered
no disease relapses during adult life. One male subject
with an extensive history of disease relapses into adult-
hood had previously had low BMD diagnosed on DXA,
and had received calcium and vitamin D mineral supple-
mentation as a result. The 27 patients from the original
cohort who did not participate in the study did not differ
from the study group in terms of sex distribution (P =
0.23), age at presentation (P = 0.81), or number of re-
lapses suffered (P = 0.46).
The mean (SD) final height Z score was −0.45 (0.92),
P = 0.007 (Fig. 1). In addition to being shorter than the
normal population, the study subjects were also signifi-
cantly overweight, with a mean (SD) BMI Z score of 1.62
(1.53), P < 0.0001 (Fig. 2): a total of 24 subjects (70.6%)
had a BMI >25 kg/m2 and 8 subjects (23.5%) >30 kg/m2.
There was no difference in height or BMI Z scores be-
tween male and female subjects (P =0.77 and P =0.54, re-
spectively). No correlation was found between the num-
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Fig. 2. Scatter-plot of Z score of BMI of the study population. The
horizontal bar represents the mean value, which was significantly higher
than zero (one sample t test).
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Fig. 3. Scatter-plots of Z and T scores of distal radial total and tra-
becular volumetric BMD of the study population. The horizontal bars
represent mean values, which were significantly lower than zero for dis-
tal radial trabecular but not total volumetric BMD (one sample t test).
ber of relapses experienced during childhood and either
height Z score (r = 0.014, P = 0.94) or BMI Z score (r =
−0.156, P = 0.38).
Distal radial trabecular vBMD (mg/cm3) was signifi-
cantly reduced: the mean (SD) Z score was –0.95 (0.99)
and T score –1.04 (1.01), both P < 0.0001 (Fig. 3). There
was, however, no reduction in distal radial total vBMD,
the mean (SD) Z score being 0.00 (0.95) and T score
−0.08 (0.99), (P = 0.99 and 0.66, respectively). No differ-
ence was detected in the reduction in trabecular vBMD
between males [mean (SD) T score −1.05 (1.11)] and fe-
males [−1.01 (0.73), P = 0.91].
The aBMD of the lumbar spine and femoral neck also
showed a reduction in T scores [−0.45 (1.27), P = 0.045
and−0.49 (0.86), P =0.002, respectively], but not Z scores
[−0.37 (1.28) and −0.15 (0.87), respectively, both P = NS]
(Fig. 4). Again, there was no difference between male
and female subjects [lumbar spine male −0.57 (1.28) vs.
female −0.16 (1.25), P = 0.40 and femoral neck [male
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Fig. 4. Scatter-plots of Z and T scores of lumbar spine (L1-L4), femoral
neck, and total hip aBMD of the study population. The horizontal bars
represent mean values, which were significantly lower than zero for the
aBMD T scores of the lumbar spine and femoral neck (one sample
t test).
−0.61 (0.76) and female −0.21 (1.05), P = 0.22]. Total hip
aBMD was not different from the control population.
A statistically significant inverse correlation was de-
tected between the number of relapses suffered and dis-
tal radial total vBMD (T score r = −0.47, P = 0.005, and
Z score r = −0.45, P = 0.008). Inverse relationships were
also found between relapse number and other measured
parameters of BMD but were not statistically significant.
Of the 24 male subjects, 19 (79.2%) had suffered a total
of 39 self-reported fractures (7 hand, 6 nose, 5 ankle, 4 fin-
ger, 3 clavicle, 3 wrist, 2 elbow, 2 rib, 2 arm, 2 toe, 1 foot,
1 leg, 1 maxilla). Nineteen fractures were related to trips
and falls, 15 were sporting injuries, 2 were acquired during
fights, and 1 was sustained during a road traffic accident.
Two fractures (both hand fractures) were not associated
with any significant trauma. Of the 10 female subjects, 3
(30%) had suffered a total of 4 fractures (3 fingers and
1 femur), all following significant trauma.
DISCUSSION
This is, to our knowledge, the first study that has in-
vestigated the impact of repeated courses of high-dose
corticosteroids used to treat relapsing MCNS throughout
childhood and adolescence on final adult height, BMI,
and BMD in both the axial and appendicular skeleton.
We have shown that our patients had significantly lower
Z scores for height and higher Z scores for BMI. These
finding are consistent with known effects of corticos-
teroids causing growth impairment in adolescents and
young adults with frequently relapsing nephrotic syn-
drome. Matsukura et al found the mean (SD) height Z
score of a population of Japanese patients with a mean
age of 27.0 years to be −0.43 (1.19), although 20 of the 86
patients were still receiving corticosteroid therapy [20].
Foote et al reported a mean height Z score of −0.22,
equivalent to a height on the 40th centile in a popula-
tion with a mean age of 15.33 years, but could find no
correlation between total corticosteroid dose adminis-
tered and final height in those who had completed their
growth [21]. Our study has also failed to show a signifi-
cant correlation between relapse frequency, used as a sur-
rogate for corticosteroid exposure and both final height
(r = 0.014, P = 0.94) and BMI (r = −0.156, P = 0.38).
Possible explanations for these findings include lack of
information on the precise cumulative dose of corticos-
teroid administered, given that a number of patients will
undoubtedly have received an unquantifiable amount of
long-term low-dose alternate-day prednisolone between
disease relapses. While corticosteroids are known to be
associated with obesity in this condition [10], it is possible
that reduced physical activity due to frequently relapsing
MCNS might have contributed to the obesity observed
in our patients.
In adults, osteoporotic fractures are an important side
effect of long-term treatment with corticosteroids [22].
Osteoporosis is characterized by a decrease in the amount
of normally mineralized bone, leading to increased bone
fragility and susceptibility to fracture. Two main factors
that influence the occurrence of osteoporotic fracture are
the peak adult bone mass (PABM), which is the amount
of bone mass gained during childhood and adolescence,
and the rate at which it is subsequently lost. It follows that
the factors affecting PABM during growth may be impor-
tant determinants of resistance to osteoporotic fracture
in later life [23]. Cross-sectional twin and family studies
suggest that genetic factors account for up to 80% of the
variation in PABM between individuals, whereas envi-
ronmental factors such as adequate nutrition (calcium,
phosphorous, protein, vitamin D) and physical activity
might influence the extent to which individuals achieve
their genetic potential for PABM [24]. High doses of
corticosteroid therapy during childhood might adversely
affect the achievement of PABM, and subsequent age-
related bone loss in such individuals will increase the
risk of fragility fractures in later adulthood. The mean Z
scores of aBMD of lumbar spine, total hip, and femoral
neck in our patients were not different from zero. Thus,
it would appear that repeated doses of high-dose steroid
therapy during childhood and adolescence do not result
in impairment of these DXA-measured variables. These
results are in agreement with those of the recent work
of Leonard et al, who used DXA of the whole body and
spine to determine BMC in 60 children with relapsing
steroid sensitive nephrotic syndrome at a mean (SD) age
of 9.0 (3.4) years [10]. In their study, after adjustments for
race, age, gender, bone area, and Tanner stage of puberty,
the whole body BMC of children and adolescents with
nephrotic syndrome was greater than that of controls,
whereas the lumbar spine BMC did not differ between
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the 2 groups. However, when the BMI Z score was in-
cluded in the regression model, BMC of the whole body
did not differ between children with nephrotic syndrome
and controls, but that of lumbar spine was lower in the
former. From these results, the authors concluded that in-
termittent treatment with high-dose corticosteroids dur-
ing growth did not appear to be associated with deficits
in the BMC of the spine or whole body.
The low mean T scores of aBMD of the lumbar spine
and femoral neck in our patients suggests that treat-
ment with corticosteroids during childhood might have
compromised the acquisition of PABM at these sites.
However, DXA provides the measurements of the total
amount of BMC (g) contained within the scanned skele-
tal site and its 2-dimensional projected bone area (BA;
cm2). It does not measure the thickness and, therefore,
the volume (cm3) that is needed for estimation of vBMD.
The aBMD is a function of bone size and its vBMD. Thus,
a short individual with smaller and narrower bones will
have lower aBMD than a taller person with larger and
thicker bones, even if the vBMD of their bones is the
same [25]. As previously stated, our patients were shorter
in relation to the UK reference population. Therefore, we
believe that their lower mean T scores, but not mean Z
scores, of aBMD of the lumbar spine and femoral neck
are likely to be due to their smaller and narrower bones
in relation to those of reference values for young adults
in the DXA manufacturer’s database, rather than lower
PABM at these sites.
In this study we also used pQCT to measure the tra-
becular and total (cortical and trabecular) vBMD at the
distal radius. Unlike the aBMD, the vBMD is less likely
to be affected by bone size [25]. The mean distal radial
trabecular vBMD Z score, but not total vBMD Z score,
was significantly lower than zero. These findings are in
keeping with those previously reported by Lettgen et al
in children with nephrotic syndrome treated with corti-
costeroids with or without cyclophosphamide [15]. It is
well known that corticosteroids are more likely to affect
trabecular bone, which has faster turnover than cortical
bone [26]. The fact that the mean distal radial total vBMD
Z score was not significantly lower than zero suggests that
the reduction in the trabecular vBMD might be offset by
cortical thickness, which serves to restore bone strength
at this site.
The unique cohort investigated in this study has al-
lowed us to study the impact of high doses of corticos-
teroids administered intermittently to treat relapses of
MCNS throughout childhood on anthropometric vari-
ables and BMD at axial and appendicular sites during
adulthood. Furthermore, MCNS allows the effect of cor-
ticosteroids on developing skeleton to be studied without
the background of inflammation, which is known to po-
tentiate the adverse effects of corticosteroids on bone
[27].
There are a number of shortcomings of this study, in-
cluding the cross-sectional design and lack of precise
information on cumulative corticosteroid doses admin-
istered, and on exercise and nutrition data throughout
childhood and adulthood. As previously mentioned, the
lack of a local control group did not allow size adjustment
of DXA-measured variables in subjects who are shorter
compared to UK reference growth data and, therefore,
are likely to have smaller and narrower bones; the Ho-
logic DXA reference data are based on U.S. adults and
the Stratec pQCT data are based on German adults. The
lack of reference data also did not allow us to evaluate
corticosteroid-induced changes in the geometric proper-
ties of the midradial cortical shell that are related to bone
strength [28].
CONCLUSION
The results of our study suggest that adult survivors
of childhood MCNS have a significant reduction in fore-
arm trabecular vBMD, placing them at increased fracture
risk at this site. A follow-up prospective study is required
in order to evaluate changes in BMD, and to determine
whether the fracture risk among individuals with low
BMD Z and T scores is increased. Results of such a study
will inform the need for interventions, such as oral cal-
cium and vitamin D supplements and antiresorptive ther-
apy, in those at high risk of fracture.
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